NV reMYND is a biotech spin-off of the University of Leuven (Belgium).

reMYND is active in the field of Alzheimer’s disease and Parkinson’s disease. In 2004 reMYND received the Flanders' Most Innovative Start-up Award. The company consists of 2 units :

• Service Unit
  • CRO mainly focused on Alzheimer transgenic mouse models with amyloid pathology.
  • In vitro genotoxicity testing & licensing of RadarScreen
• Drug Discovery Unit focused on tau (as target for Alzheimer's disease) and α-synuclein (as target for Parkinson's disease).